Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

12. Juni 2019 aktualisiert von: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

876

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • China
      • Beijing, China, 100050
        • Novartis Investigative Site
      • Chongqing, China, 400037
        • Novartis Investigative Site
      • Shanghai City, China
        • Novartis Investigative Site
    • Beijing
      • Beijing, Beijing, China, 100039
        • Novartis Investigative Site
      • Beijing, Beijing, China, 100037
        • Novartis Investigative Site
    • Gansu
      • Lanzhou, Gansu, China, 730030
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, China, 51000
        • Novartis Investigative Site
      • Guangzhou, Guangdong, China, 510515
        • Novartis Investigative Site
    • Jiangsu
      • Suzhou, Jiangsu, China, 215006
        • Novartis Investigative Site
      • Yangzhou, Jiangsu, China
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, China, 110000
        • Novartis Investigative Site
      • Shenyang, Liaoning, China, 110003
        • Novartis Investigative Site
    • Shanghai
      • Jinshan, Shanghai, China, 201508
        • Novartis Investigative Site
      • Shanghai, Shanghai, China, 200032
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, China, 710061
        • Novartis Investigative Site
    • Tianjin
      • Tianjin, Tianjin, China, 300121
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310013
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, China, 325000
        • Novartis Investigative Site
  • Indien
      • Rajasthan, Indien, 334003
        • Novartis Investigative Site
    • Delhi
      • New Delhi, Delhi, Indien, 110029
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, Indien, 380054
        • Novartis Investigative Site
      • Vadodara, Gujarat, Indien, 390022
        • Novartis Investigative Site
    • Maharashtra
      • Nagpur, Maharashtra, Indien, 440010
        • Novartis Investigative Site
      • Nagpur, Maharashtra, Indien, 440012
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, Indien, 600101
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Indien, 500082
        • Novartis Investigative Site
  • Japan
      • Osaka, Japan, 534-0021
        • Novartis Investigative Site
      • Saitama, Japan, 330 8503
        • Novartis Investigative Site
    • Aichi
      • Nagakute-city, Aichi, Japan, 480-1195
        • Novartis Investigative Site
      • Seto-city, Aichi, Japan, 489-8642
        • Novartis Investigative Site
    • Chiba
      • Kamogawa-city, Chiba, Japan, 2968602
        • Novartis Investigative Site
    • Ehime
      • Saijo-city, Ehime, Japan, 793-0027
        • Novartis Investigative Site
    • Fukuka
      • Chikushino-city, Fukuka, Japan, 818-8516
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka-city, Fukuoka, Japan, 810-0001
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japan, 811-0213
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japan, 815-8588
        • Novartis Investigative Site
      • Iizuka-city, Fukuoka, Japan, 820-8505
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japan, 830-8543
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japan, 830-8577
        • Novartis Investigative Site
    • Gifu
      • Ogaki-city, Gifu, Japan, 503-8502
        • Novartis Investigative Site
    • Hokkaido
      • Kushiro-city, Hokkaido, Japan, 085-0062
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, Japan, 006-8555
        • Novartis Investigative Site
    • Hyogo
      • Amagasaki city, Hyogo, Japan, 660 8550
        • Novartis Investigative Site
      • Kobe-City, Hyogo, Japan, 654-0155
        • Novartis Investigative Site
    • Ibaraki
      • Mito-city, Ibaraki, Japan, 311-4198
        • Novartis Investigative Site
    • Ishikawa
      • Kanazawa, Ishikawa, Japan, 920 8650
        • Novartis Investigative Site
    • Kagawa
      • Kanonji-city, Kagawa, Japan, 769-1695
        • Novartis Investigative Site
      • Takamatsu city, Kagawa, Japan, 760 8557
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki-city, Kanagawa, Japan, 211-8533
        • Novartis Investigative Site
      • Yokohama city, Kanagawa, Japan, 232 0024
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japan, 236 0051
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japan, 227-8501
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japan, 231-8682
        • Novartis Investigative Site
    • Kochi
      • Kochi city, Kochi, Japan, 781 8555
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto-city, Kumamoto, Japan, 861-4193
        • Novartis Investigative Site
      • Yatsushiro-city, Kumamoto, Japan, 866-8660
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city, Kyoto, Japan, 607-8062
        • Novartis Investigative Site
      • Uji-city, Kyoto, Japan, 611-0042
        • Novartis Investigative Site
    • Miyagi
      • Sendai-city, Miyagi, Japan, 981-3133
        • Novartis Investigative Site
    • Nagano
      • Nakano-city, Nagano, Japan, 383-8505
        • Novartis Investigative Site
      • Saku-city, Nagano, Japan, 3850051
        • Novartis Investigative Site
      • Ueda-city, Nagano, Japan, 386-8610
        • Novartis Investigative Site
    • Niigata
      • Niigata-city, Niigata, Japan, 950-1197
        • Novartis Investigative Site
    • Osaka
      • Osaka-city, Osaka, Japan, 540-0006
        • Novartis Investigative Site
    • Saitama
      • Kawaguchi-city, Saitama, Japan, 333-0842
        • Novartis Investigative Site
      • Sayama-city, Saitama, Japan, 350-1323
        • Novartis Investigative Site
      • Wako-city, Saitama, Japan, 351-0102
        • Novartis Investigative Site
    • Shiga
      • Kusatsu city, Shiga, Japan, 525 8585
        • Novartis Investigative Site
    • Shizuoka
      • Hamamatsu-city, Shizuoka, Japan, 430-8558
        • Novartis Investigative Site
      • Kakegawa-city, Shizuoka, Japan, 436-8555
        • Novartis Investigative Site
    • Tokyo
      • Akishima-city, Tokyo, Japan, 196-0003
        • Novartis Investigative Site
      • Chuo ku, Tokyo, Japan, 104-8560
        • Novartis Investigative Site
      • Hachioji-city, Tokyo, Japan, 192-0918
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, Japan, 173-8610
        • Novartis Investigative Site
      • Musashino-city, Tokyo, Japan, 180-8610
        • Novartis Investigative Site
      • Shinagawa ku, Tokyo, Japan, 141 8625
        • Novartis Investigative Site
      • Shinagawa-ku, Tokyo, Japan, 142-8666
        • Novartis Investigative Site
    • Wakayama
      • Tanabe-city, Wakayama, Japan, 646-8558
        • Novartis Investigative Site
  • Jordanien
      • Amman, Jordanien, 11183
        • Novartis Investigative Site
      • Amman, Jordanien, 11184
        • Novartis Investigative Site
    • JOR
      • Amman, JOR, Jordanien, 11152
        • Novartis Investigative Site
  • Korea, Republik von
      • Busan, Korea, Republik von, 602739
        • Novartis Investigative Site
      • Gwangju, Korea, Republik von, 61469
        • Novartis Investigative Site
      • Incheon, Korea, Republik von, 405 760
        • Novartis Investigative Site
      • Seoul, Korea, Republik von, 03080
        • Novartis Investigative Site
      • Seoul, Korea, Republik von, 03722
        • Novartis Investigative Site
      • Seoul, Korea, Republik von, 02841
        • Novartis Investigative Site
    • Bucheon Si
      • Gyeonggi do, Bucheon Si, Korea, Republik von, 422-711
        • Novartis Investigative Site
    • Chungcheongbuk Do
      • Cheongju si, Chungcheongbuk Do, Korea, Republik von, 28644
        • Novartis Investigative Site
    • Gangwon-do
      • Wonju, Gangwon-do, Korea, Republik von, 26427
        • Novartis Investigative Site
    • Gyeonggi Do
      • Bundang Gu, Gyeonggi Do, Korea, Republik von, 13620
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, Korea, Republik von, 05505
        • Novartis Investigative Site
      • Seoul, Korea, Korea, Republik von, 06351
        • Novartis Investigative Site
      • Seoul, Korea, Korea, Republik von, 08308
        • Novartis Investigative Site
    • Seocho Gu
      • Seoul, Seocho Gu, Korea, Republik von, 06591
        • Novartis Investigative Site
  • Libanon
      • Ashrafieh, Libanon, 166830
        • Novartis Investigative Site
      • Beirut, Libanon, 1107 2020
        • Novartis Investigative Site
      • Beirut, Libanon
        • Novartis Investigative Site
      • Hazmieh, Libanon, 470
        • Novartis Investigative Site
  • Malaysia
      • Kuala Lumpur, Malaysia, 59100
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia, 50400
        • Novartis Investigative Site
    • MYS
      • Kuala Lumpur, MYS, Malaysia, 56000
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu, Sabah, Malaysia, 88300
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malaysia, 94300
        • Novartis Investigative Site
    • Selangor Darul Ehsan
      • Kuala Lumpur, Selangor Darul Ehsan, Malaysia, 43000
        • Novartis Investigative Site
      • Sungai Buloh, Selangor Darul Ehsan, Malaysia, 47000
        • Novartis Investigative Site
  • Philippinen
      • Makati City, Philippinen, 1229
        • Novartis Investigative Site
      • Manila, Philippinen, 1003
        • Novartis Investigative Site
      • Pasig City, Philippinen, 1605
        • Novartis Investigative Site
      • Quezon City, Philippinen, 1102
        • Novartis Investigative Site
      • Quezon City, Philippinen, 1113
        • Novartis Investigative Site
      • San Juan City, Philippinen, 1500
        • Novartis Investigative Site
    • Manila
      • Quezon City, Manila, Philippinen, 1100
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, Philippinen, 1000
        • Novartis Investigative Site
  • Singapur
      • Singapore, Singapur, 169609
        • Novartis Investigative Site
      • Singapore, Singapur, 117549
        • Novartis Investigative Site
  • Taiwan
      • Changhua, Taiwan, 50006
        • Novartis Investigative Site
      • Kaohsiung, Taiwan, 80756
        • Novartis Investigative Site
      • Kaohsiung City, Taiwan, 83301
        • Novartis Investigative Site
      • New Taipei, Taiwan, 22060
        • Novartis Investigative Site
      • Taichung, Taiwan, 40447
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Novartis Investigative Site
      • Taipei, Taiwan, 11217
        • Novartis Investigative Site
      • Taipei, Taiwan, 10449
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Novartis Investigative Site
      • Yilan, Taiwan, 26058
        • Novartis Investigative Site
  • Thailand
      • Bangkok, Thailand, 10330
        • Novartis Investigative Site
      • Bangkok, Thailand, 10700
        • Novartis Investigative Site
      • Bangkok, Thailand, 10400
        • Novartis Investigative Site
      • Chiang Mai, Thailand, 50200
        • Novartis Investigative Site
      • Muang, Thailand, 40002
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Thailand, 90110
        • Novartis Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Male or female ≥ 18 years of age, with body weight ≤160 kg

  • Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:

    • Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
    • Pulmonary congestion on chest radiograph
    • Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
  • Systolic BP ≥125 mmHg at the start and at the end of screening
  • Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
  • Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
  • Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).

Exclusion Criteria:

  • Dyspnea primarily due to non-cardiac causes
  • Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).

  • Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment

    *Patients with systolic blood pressure >180 mmHg at the end of screening

  • AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute

  • Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).

    *Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis

  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
Arzneimittel: Placebo
Intravenöse Infusion
Sonstiges: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Experimental: Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
Sonstiges: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Arzneimittel: Serelaxin
Intravenöse Infusion

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
Zeitfenster: through day 5
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
through day 5

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to WHF
Zeitfenster: Through Day 5
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
Through Day 5
Time to CV Death
Zeitfenster: Through Day 180
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
Through Day 180
Time to All-cause Death
Zeitfenster: Through Day 180
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
Through Day 180
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
Zeitfenster: Through Day 5
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
Through Day 5
Dyspnea by VAS-AUC Changes
Zeitfenster: Through Day 5
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
Through Day 5
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
Zeitfenster: Up to day 30
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
Up to day 30
Renal Dysfunction and Prevention of Worsening of Renal Function
Zeitfenster: Through Day 5
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
Through Day 5
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
Zeitfenster: Through Day 180
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
Through Day 180
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
Zeitfenster: Through Day 180
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
Through Day 180
Time to In-hospital Worsening Heart Failure Through Day 5
Zeitfenster: Through Day 5
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
Through Day 5
Use of Loop Diuretic and Vasoactive Agents
Zeitfenster: Through Day 5
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
Through Day 5
Change From Baseline in Cardio-renal Biomarkers
Zeitfenster: Day 2 and Day 5
Day 2 and Day 5
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
Zeitfenster: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Novartis Pharmaceuticals

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

12. März 2014

Primärer Abschluss (Tatsächlich)

27. März 2017

Studienabschluss (Tatsächlich)

16. Juni 2017

Studienanmeldedaten

Zuerst eingereicht

20. November 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. Dezember 2013

Zuerst gepostet (Schätzen)

11. Dezember 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

2. August 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. Juni 2019

Zuletzt verifiziert

1. Juni 2019

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CRLX030A2302

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Akute Herzinsuffizienz

Klinische Studien zur Placebo

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Guinea

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren